TD Cowen analyst Ritu Baral raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $554 from $390 and keeps a Buy rating on the shares. The firm updated its model following last week’s EU approval of Resdiffra including reducing the discount rate on lower risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra’s European Market Breakthrough
- Madrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMP
- Madrigal gets conditional marketing authorization for Rezdiffra from EC
- Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities
- Novo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease